This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Cardiopulmonary Bypass or Altered Heparin Response
and you are
over 18
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study will explore altered heparin responsiveness (AHR) in cardiac surgical patients undergoing cardiopulmonary bypass (CPB) requiring systemic anticoagulation with heparin. The investigators will evaluate the hypothesis that AHR may be directly related to, modulated or mediated by interactions between heparin, antithrombin (AT), the heparin-AT complex, and one or more acute phase proteins. The investigators are particularly interested in identifying patients with "true heparin resistance", that is, patients who demonstrate AHR even after antithrombin-replenishment in the presence of an adequate systemic dose of heparin.

Provided treatments

  • Drug: Heparin
  • Drug: ATryn
Tris trial is registered with FDA with number: NCT01598883. The sponsor of the trial is Massachusetts General Hospital and it is looking for 504 volunteers for the current phase.
Official trial title:
Understanding "Heparin Resistance" in Cardiac Surgery: Altered Heparin Responsiveness and Its Association With Acute Inflammatory Reactions